Recently, Run-Long Medtech completed a round of financing of 100 million yuan, led by maixing investment and Xingze capital, with Gelu capital as the exclusive financial consultant. This round of financing will be mainly used for product research and development, accelerate the process of product commercialization, and deeply layout the sports medicine industry.
Run-Long Medtech is an innovative medical device company focusing on the field of sports medicine and laying out the domestic high-end market. Mr. Wang zhongran, chairman of the board of directors, has been deeply engaged in orthopedics for 23 years. He has led the international famous sports medicine brand to obtain the first market share in China for 17 years in a row, far ahead of the competitors, and once occupied 70% of the domestic market share of Sports Medicine. As a senior expert in the industry, he has a deep understanding of products and markets, and has a wide range of sports medicine industry resources.
Huge prospect: the market scale of sports medicine will reach more than 5 billion yuan in 2023
Sports medicine, originated from orthopedic trauma, is a basic research and clinical comprehensive application subject combining medicine and sports. It mainly deals with the injuries and lesions of bone and joint, muscle, tendon, ligament, cartilage, meniscus, synovium and other tissues related to sports.
Sports medicine is a subdivision field in orthopedics, but it is in a rapid growth stage both in the global market and in the domestic market. According to the data of global market insights, the market size of global sports medicine will exceed 9 billion US dollars in 2025, with an average annual growth rate of nearly 8%. The growth rate of sports medicine in China is more rapid. According to the special report of orthopedic sports medicine in the pharmaceutical industry, the market scale of sports medicine in China is expected to exceed 5 billion yuan in 2023.
Due to the high technical barriers and patent technology blockade, China's sports medicine is still in the state of import monopoly. International giants such as Smith & nephew, Ruishi, Johnson & Johnson and Stryker have occupied more than 90% of the domestic market share for a long time. With the rise of China's medical device industry and the rapid growth of market demand, and in the environment of high fitness incidence rate and high incidence of aging population, the potential market demand is constantly being stimulated. The domestic medical device market is growing and expanding. Sports medical industry is ready to go, and the future growth can be expected.
Eye catching: the perfect combination of high-end team and superior products
In the process of witnessing and promoting the growth of China's sports medicine from scratch, Mr. Wang zhongran saw the historical opportunity of the industry and was determined to invest in the tide of import substitution. With the goal of providing international level and domestic leading products, he provided Chinese doctors with high-quality domestic products. Through the establishment of excellent product quality management system and perfect service, he made ruilongtaike a foreign enterprise In the monopolized market, it occupies an important place.
Talent is the first element of enterprise development. Mr. Wang zhongran has experienced in supply chain management, product sales and channel management at home and abroad in sports medicine. At the same time, in practice, ruilang Tyco has also built a very excellent management team. The core executives have more than 10 years of experience in product lifecycle management in relevant professional fields.
In terms of products, the management has a deep understanding of clinical needs and continuously invests in technology research and development. The company has a complete product structure and technical reserves, covering high-value consumables, power systems and surgical tools, among which core products such as planer, anchor with thread, titanium plate with loop have been put on the market. At present, it has been used in many top sports medicine hospitals in China, and has been highly recognized by marketing peers and clinical experts. In terms of product development strategy, the company improves the technology and process of each product to the extreme, takes product performance as the foothold to compete with international giants, and provides the best products to all demanders.
Product quality plays a decisive role in whether the wave of "import substitution" can continue. Based on the clinical needs, we strictly and accurately control the environment of the products, complete the ISO13485 system certification, fully integrate the international advantage resources, and successfully promote the world-class products.
As a key product in the early stage, the planing cutter head of rilantake integrates the global advantageous resources in design and processing. The processing technology, welding accuracy and coaxiality ensure the smooth effect of high-speed rotary cutting. The rotational speed of the grinding head can reach 12000 rpm, and the circular runout of the cutter head is controlled within 5um. The noise is very low, and there is no interference between the inner and outer cutter heads. After the actual test of more than 20000 patients, the performance of the product is completely comparable to or even better than that of international brands. In terms of low-temperature plasma blade, the temperature control of rilantake's products has reached 41 degrees, which is significantly ahead of that of its peers at 45 degrees. With a good market entry point of view, as well as the high quality and reliability of products, rylatek has established a high-quality domestic brand image among customers.
Layout the future: accelerate the commercialization of products and expand the service coverage
Sports medical equipment has high technical barriers. If domestic brands only rely on rapid evidence collection to compete with imported brands in the whole product line, it will be very difficult for them to rise. Mr. Wang zhongran has a deep insight into the current situation of the industry, and has formulated a corresponding development stage fit strategy for rylateco. "We first choose to enter the two fields of planing cutter head and low-temperature plasma cutter head. They are general-purpose instruments in the field of sports medicine. The market scale is large enough, accounting for 25% of the market share of sports medicine, and can cover all customers. They are the most common and most demanding fields, but the domestic performance and quality can not meet the clinical needs."
With the help of the market development of these two competitive products, the company has already occupied a pivotal position in the field of sports medicine, and has established a high-end domestic brand image, which has laid a solid foundation for the promotion of other products.
If the first stage is to focus on the development of products with fast access and large market capacity, and constantly consolidate the quality, concentrate resources to quickly occupy the specific target market; the next stage is to further expand the product line, establish a complete product portfolio, and provide comprehensive solutions for sports medicine surgery. Currently, the company's registered products include planer, titanium alloy anchor with thread, titanium plate with loop, non absorbable surgical suture and arthroscopic access cannula. In 2021, the company will complete product registration in many product categories, such as PEEK interface screw, shoulder joint internal and external row screw, meniscus suture device, etc., and the consumables will be fully certified to provide users with high-quality and cost-effective domestic sports medicine products Products.
Relying on the advantages of high-performance products, brand foundation and resources, we will make our products truly benefit people's livelihood, make its services cover more people in need, add luster to "made in China", and promote the development of the whole sports medicine industry in China.
As the investor of this round, Li Xin, partner of maxtar investment, said, "the team of rylateco has the richest industry experience. The founder of the company has witnessed and deeply participated in the start and development of sports medicine in China almost from the beginning. We strongly recognize the high quality product strategy that the company adheres to, and value the team's valuable indigenous innovation in the booming industrial development. "
As the investor in this round, Qiang Jing, managing partner of Xingze capital, said, "ruilangtaike is an enterprise that perfectly matches Xingze's investment philosophy. We are optimistic about the entrepreneurial characteristics and strategic vision of the founding team, and highly appreciate the rapid development of the company since its establishment. I believe that with the efforts of Wang zhongran and the whole team, the company will make great progress. "
Cao Zheng, managing partner of Watson investment, who completed the investment in Angel round, said: "Watson investment became the angel round investor of the company in 2018, witnessing the company's journey from product research and development to clinical and market entry. In the past three years of pleasant cooperation, we deeply feel the founder's excellent grasp of the product portfolio and the excellent execution of the team. After the introduction of new investors this time, it will be more conducive to the leading edge of the company's follow-up product line, and will more actively promote the market, so as to let more patients use high-performance sports medicine products belonging to the Chinese people. "
About maixing investment
Founded in 2004, maixing investment is a private equity fund management organization specializing in equity investment business. Its investment fields mainly focus on consumption, medical treatment and technology. Maixing investment has been focusing on a few specific fields for more than ten years. With its profound insight into the nature of business and the laws of the industry, it has maintained a high level of return on investment in the industry for a long time. Whether in the process of investment practice or self-development, maxstar investment always emphasizes social responsibility and is committed to becoming a respected professional investment institution.
About Xingze capital
Xingze capital was established in 2015 under the name of "Xingze", aiming to integrate the resources of big health industry with the help of capital, promote the development of the industry and promote the development of human beings. Xingze capital always adheres to promoting the innovation and growth of Chinese enterprises. With its investment team's rich industry experience and global resource network, it spare no effort to help entrepreneurs realize their entrepreneurial dream.
About Wosheng capital
Founded in 2016, Watson investment is a fund focusing on early and medium-term investment opportunities in the biomedical field. We have invested in many star enterprises in China and the United States. We have a deep understanding of gene editing, multi omics and other technologies. We have established a number of international top scientists and continuous entrepreneurs in the fields of innovative drugs and therapies, diagnosis and detection, including xunbaihui biology, Prix benchmark and Lanyu biology , intelligent nuclear organisms, Tuoxin Tiancheng organisms, etc. The cornerstone LP of Watson investment is a number of powerful pharmaceutical listed companies, all of which are domestic leaders in subdivided fields.
|
